Compare FLYX.WS & XCUR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
flyExclusive Inc. Redeemable warrants each whole warrant exercisable for one Class A common stock at an exercise price of $11.50 per share
Current Price
Current Price
| Metric | FLYX.WS | XCUR |
|---|---|---|
| Founded | N/A | 2011 |
| Country | | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 9.6M | 9.2M |
| IPO Year | N/A | 2017 |
| Metric | FLYX.WS | XCUR |
|---|---|---|
| Price | $0.14 | $1.11 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | N/A | ★ 76.6K |
| Earning Date | N/A | 11-27-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 83.37 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | $44.02 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ N/A | N/A |
| 52 Week Low | N/A | $0.78 |
| 52 Week High | N/A | $9.48 |
| Indicator | FLYX.WS | XCUR |
|---|---|---|
| Relative Strength Index (RSI) | N/A | 50.72 |
| Support Level | N/A | $0.96 |
| Resistance Level | N/A | $1.52 |
| Average True Range (ATR) | 0.00 | 0.13 |
| MACD | 0.00 | 0.02 |
| Stochastic Oscillator | 0.00 | 70.95 |
Exicure Inc is a clinical-stage biotechnology company focused on developing treatments for blood-related diseases, with an emphasis on small-molecule therapies that have the potential to benefit a broad range of patients. The company acquired GPCR Therapeutics USA and secured a license for GPC-100 (Burixafor), a clinical-stage small-molecule compound that inhibits the chemokine receptor CXCR4. GPC-100 has demonstrated the ability to effectively mobilize various cell types, including hematopoietic stem cells and lymphocytes, highlighting its broad therapeutic potential across multiple indications.